CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cbay · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CymaBay Therapeutics, Inc. (CBAY) measures how much investors pay for each dollar of the company's trailing earnings. CBAY's current PE ratio of N/A is calculated by dividing its stock price of $32.48 by its TTM earnings per share of -$0.99.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2012 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CymaBay Therapeutics, Inc.You CBAY | $3.7B | N/A | — | -$0.99 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 Chinook Therapeutics, Inc. KDNY | $2.7B | N/A | — | -$2.87 |
 Longboard Pharmaceuticals, Inc. LBPH | $2.3B | N/A | — | -$2.39 |
 MorphoSys AG MOR | $2.9B | N/A | — | -$1.38 |
 Morphic Holding, Inc. MORF | $2.9B | N/A | — | -$3.59 |
 Mirati Therapeutics, Inc. MRTX | $4.1B | N/A | — | -$13.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-0.99 | — | |
2022-12-31 FY2022 | — | $-1.35 | — | |
2021-12-31 FY2021 | — | $-1.30 | — | |
2020-12-31 FY2020 | — | $-0.71 | — | |
2019-12-31 FY2019 | — | $-1.53 | — | |
2018-12-31 FY2018 | — | $-1.25 | — | |
2017-12-31 FY2017 | — | $-0.79 | — | |
2016-12-31 FY2016 | — | $-1.14 | — | |
2015-12-31 FY2015 | — | $-0.82 | — | |
2014-12-31 FY2014 | — | $-2.65 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CymaBay Therapeutics, Inc. (CBAY) measures how much investors pay for each dollar of the company's trailing earnings. CBAY's current PE ratio of N/A is calculated by dividing its stock price of $32.48 by its TTM earnings per share of -$0.99.
Frequently asked questions
CBAY pe ratio · 6 questionsCBAY's current PE ratio is N/A as of 2026-06-09, based on a stock price of $32.48 and TTM EPS of -$0.99. Data sourced from Financial Modeling Prep via CBAY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CymaBay Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09